372 results match your criteria Urticaria Solar


Study of Minimal Erythema Dose in a Series of Solar Urticaria.

Actas Dermosifiliogr 2021 Jun 1;112(6):546-550. Epub 2021 Feb 1.

Departamento de Dermatología, Hospital Universitario de La Princesa, Madrid, Spain.

Background: Reduced minimal erythema dose (MED) is an abnormal erythematous reaction to light according to the skin phototype, which is determined by phototest. MED is reduced or abnormal in some photodermatoses. However, we have not found information about reduced MED in patients with solar urticarial (SU), a condition which causes hives after sun exposure. Read More

View Article and Full-Text PDF

Isolated solar angioedema: A systematic review of the literature.

Photodermatol Photoimmunol Photomed 2021 Mar 19. Epub 2021 Mar 19.

Photodermatosis Service, Division of Dermatology, Rabin Medical Center, Petah Tikva, Israel.

Solar urticaria is a well-recognized photodermatosis, sometimes accompanied by angioedema. However, isolated solar angioedema (ISA) is a rare and unrecognized entity. The purpose of our work was to systematically review the available data on ISA. Read More

View Article and Full-Text PDF

Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications.

J Drugs Dermatol 2021 03;20(3):290-294

Afamelanotide (SCENESSE®) is a synthetic analogue of α-melanocyte-stimulating hormone that is FDA-approved to increase pain-free sunlight exposure in adult patients with erythropoietic protoporphyria. Its dual photoprotective and anti-inflammatory effects also make it a promising therapy for other photosensitive dermatologic diseases that are resistant to treatment. The PubMed/MEDLINE and ClinicalTrials. Read More

View Article and Full-Text PDF

Study of Minimal Erythema Dose in a Series of Solar Urticaria.

Actas Dermosifiliogr 2021 Jun 16;112(6):546-550. Epub 2020 Dec 16.

Departamento de Dermatología, Hospital Universitario de La Princesa, Madrid, España.

Background: Reduced minimal erythema dose (MED) is an abnormal erythematous reaction to light according to the skin phototype, which is determined by phototest. MED is reduced or abnormal in some photodermatoses. However, we have not found information about reduced MED in patients with solar urticarial (SU), a condition which causes hives after sun exposure. Read More

View Article and Full-Text PDF

Ultraviolet A rush hardening for chronic actinic dermatitis: Pilot treatment outcomes.

J Dermatol 2021 Mar 2;48(3):385-388. Epub 2020 Dec 2.

Dermatology Hospital, Southern Medical University, Guangzhou, China.

Chronic actinic dermatitis (CAD) is a common debilitating photodermatosis. Patients often have to completely avoid outdoor activities, which severely impacts their quality of life. Phototherapy is effective for CAD and seems to increase patients' tolerance towards sunlight and consequently decrease the extent of disease. Read More

View Article and Full-Text PDF

Lichturtikaria: Klinik, Diagnostik, Verlauf und Therapiemanagement bei 27 Patienten.

J Dtsch Dermatol Ges 2020 Nov;18(11):1261-1269

Zentrums für Dermatologie, HELIOS Universitätsklinikum Wuppertal, Universität Witten-Herdecke, Wuppertal.

Background And Objectives: Solar urticaria is a rare photodermatosis, yet lacking standardization in diagnosis and therapy. The aim of this research was to use innovative radiation sources for diagnostics with defines and reproducible emission spectrum and doses. A uniform therapy step scheme was to be created. Read More

View Article and Full-Text PDF
November 2020

Wood's Lamp as an Inexpensive, Handy Tool to Diagnose Solar Urticaria.

Indian Dermatol Online J 2020 Sep-Oct;11(5):833-834. Epub 2020 Sep 19.

Department of Dermatology, All India Institute of Medical Sciences, Nagpur, Maharashtra, India.

View Article and Full-Text PDF
September 2020

Solar urticaria: Clinic, diagnostic, course and therapy management in 27 patients.

J Dtsch Dermatol Ges 2020 Nov 16;18(11):1261-1268. Epub 2020 Nov 16.

Department of Dermatology, HELIOS University Hospital Wuppertal, University of Witten-Herdecke, Wuppertal, Germany.

Background And Objectives: Solar urticaria is a rare photodermatosis, the diagnosis and therapy of which have not yet been standardized. The aim of this research was to use innovative radiation sources for diagnostics with defined and reproducible emission spectra and doses. A uniform therapy step scheme was to be created. Read More

View Article and Full-Text PDF
November 2020

Chronic inducible urticaria: classification and prominent features of physical and non-physical types.

Acta Dermatovenerol Alp Pannonica Adriat 2020 Sep;29(3):141-148

Clinical Department of Dermatovenereology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.

Chronic inducible urticaria (CIndU) is a common inflammatory skin condition characterized by the recurrence of itchy wheals and/or angioedema that lasts more than 6 weeks and is induced by specific physical or environmental stimuli (cold, heat, exercise, pressure, sunlight, vibration, water, etc.). According to the current international classification, it includes physical urticarias (dermographism, delayed-pressure urticaria, exercise-induced urticaria, cold urticaria, heat urticaria, solar urticaria, and vibratory urticaria) and non-physical urticarias caused by exposure to specific stimuli (cholinergic urticaria, contact urticaria, and aquagenic urticaria). Read More

View Article and Full-Text PDF
September 2020

[Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide].

Ned Tijdschr Tandheelkd 2020 Apr;127(4):237-243

The medicament afamelanotide is an analogue of endogenous ?-melanocyte-stimulating hormone. It promotes cutaneous pigmentation, providing protection from sunlight. In dermatology, afamelanotide seems to establish therapeutic results for polymorphic light eruption, solar urticaria, erythropoietic protoporphyria, Hailey-Hailey disease, vitiligo and acne vulgaris. Read More

View Article and Full-Text PDF

Good things come to those who wait: Successful response of solar urticaria to omalizumab after 1 year of treatment.

Photodermatol Photoimmunol Photomed 2020 Sep 1;36(5):408-411. Epub 2020 Jun 1.

Dermatology Unit, University of Rome Tor Vergata, Rome, Italy.

View Article and Full-Text PDF
September 2020

Establishment of the basophil activation test to detect photoallergens in solar urticaria.

J Allergy Clin Immunol Pract 2020 09 26;8(8):2817-2819.e1. Epub 2020 Apr 26.

Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, Japan.

View Article and Full-Text PDF
September 2020

Transient Pruritic Erythema as a Forme Fruste of Solar Urticaria.

Isr Med Assoc J 2020 Apr;22(4):227-231

Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Background: Solar urticaria (SU) is a rare and disabling photodermatosis. SU typically manifests as urticarial wheals and erythema appearing shortly after sun exposure. SU is often initially diagnosed clinically with subsequent confirmation through photoprovocation tests. Read More

View Article and Full-Text PDF

A qualitative study of knowledge, behaviour and attitudes regarding vitamin D acquisition among patients with photosensitivity disorders.

Photodermatol Photoimmunol Photomed 2020 Sep 27;36(5):378-383. Epub 2020 Apr 27.

Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology Medicine and Health, Centre for Dermatology Research, School of Biological Sciences, University of Manchester, Manchester Academic Health Science Centre and Salford Royal NHS Foundation Trust, Manchester, UK.

Background: Cutaneous exposure to sunlight is a major source of vitamin D. Individuals with photosensitivity disorders have symptoms provoked by sunlight and may not achieve the brief sunlight exposures that convey vitamin D acquisition.

Objective: To explore knowledge, behaviour and attitudes towards vitamin D and its acquisition in patients with photosensitivity. Read More

View Article and Full-Text PDF
September 2020

Solar urticaria caused by visible light in a 33-year-old male refractory to treatment with omalizumab.

Photodermatol Photoimmunol Photomed 2020 07 21;36(4):316-317. Epub 2020 Mar 21.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

View Article and Full-Text PDF

Comparison of racial distribution of photodermatoses in USA academic dermatology clinics: A multicenter retrospective analysis of 1080 patients over a 10-year period.

Photodermatol Photoimmunol Photomed 2020 May 12;36(3):233-240. Epub 2020 Mar 12.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

Background: Previous studies at single academic institutions have identified variations in the prevalence of photodermatoses among racial groups. The purpose of the study was to compare the distribution of photodermatoses between Whites and Blacks at four academic medical centers in the USA.

Methods: A retrospective chart review was performed at four institutions' general dermatology clinics using diagnoses consistent with the International Classification of Disease (ICD), Ninth and Tenth Revisions, codes related to photodermatoses between August 2006 and August 2016. Read More

View Article and Full-Text PDF

Characteristics and clinical significance of augmentation spectra in solar urticaria.

J Dermatol 2020 Apr 21;47(4):369-377. Epub 2020 Jan 21.

Department of Dermatology, Kansai Medical University, Osaka, Japan.

Solar urticaria has unique spectra, such as inhibition and augmentation. The clinical significance of these spectra, especially augmentation, is not well understood. Reported cases of solar urticaria with augmentation spectra are extremely rare in the published English-language work. Read More

View Article and Full-Text PDF

Phototherapy in the Evaluation and Management of Photodermatoses.

Dermatol Clin 2020 Jan 18;38(1):71-77. Epub 2019 Oct 18.

Department of Dermatology, Henry Ford Health System, 3031 West Grand Boulevard, Suite 800, Detroit, MI 48202, USA. Electronic address:

Ultraviolet light (UV) and visible light are important components in the diagnosis of photodermatoses, and UV has the unique ability to also be used to manage photodermatoses. Phototesting, provocative light testing, and photopatch testing can provide important information in diagnosing patients with photodermatoses; phototesting can be used to determine the starting dose for phototherapy in these patients. Once photosensitivity is established, narrowband UVB and UVA1 therapy have helped to improve the quality of life of photosensitive patients, such as those with polymorphous light eruption, chronic actinic dermatitis, and solar urticaria. Read More

View Article and Full-Text PDF
January 2020

Solar urticaria treated with omalizumab.

Cutis 2019 Jul;104(1):E4-E5

Allergy and Immunology Service, Tripler Army Medical Center, Honolulu, Hawaii, USA.

View Article and Full-Text PDF

Incapacitating solar urticaria: successful treatment with omalizumab.

An Bras Dermatol 2019 07 29;94(3):331-333. Epub 2019 Jul 29.

Dermatology Department, Centro Hospitalar de Leiria, Leiria, Portugal.

Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Read More

View Article and Full-Text PDF

Solar Urticaria, a Disease with Many Dark Sides: Is Omalizumab the Right Therapeutic Response? Reflections from a Clinical Case Report.

Open Med (Wars) 2019 7;14:403-406. Epub 2019 Jun 7.

Department of Life, Health and Environmental Sciences, University of L'Aquila, Italy Allergy an Clinical Immunology Unit, AUSL 04 Teramo, Italy.

Solar urticaria is a rare type of photodermatosis that significantly reduces the quality of life of the subjects affected, with a risk of anaphylaxis should the entire body be exposed to the sun. Patients are forced to modify and limit their normal activities, and since the symptoms are triggered by exposure to sun, which is difficult if not impossible to avoid in everyday life, a safe and effective therapy appears to be essential. Unfortunately, traditional therapies in a discrete number of patients are unable to provide adequate and safe answers. Read More

View Article and Full-Text PDF

Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab.

J Am Acad Dermatol 2019 May 28. Epub 2019 May 28.

Dermatology Department, Photobiology Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain. Electronic address:

View Article and Full-Text PDF

Evaluation of nine patients with solar urticaria during summer.

G Ital Dermatol Venereol 2020 Dec 29;155(6):800-802. Epub 2019 Mar 29.

Unit of Allergological and Occupational Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

View Article and Full-Text PDF
December 2020

Real-life experience in the treatment of solar urticaria: retrospective cohort study.

Clin Exp Dermatol 2019 Jul 13;44(5):e164-e170. Epub 2019 Apr 13.

Photodermatosis Service, Department of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.

Background: Solar urticaria (SU) is a rare photodermatosis causing a significant impact on patients' quality of life (QoL), and treatment is often challenging.

Aim: To analyse clinical experience with a tailored stepwise therapeutic approach.

Methods: A retrospective cohort design was used. Read More

View Article and Full-Text PDF

Solar urticaria - An Australian case series of 83 patients.

Australas J Dermatol 2019 May 25;60(2):110-117. Epub 2018 Dec 25.

St Vincent's Hospital, Melbourne, Victoria, Australia.

Solar urticaria (SU) is a rare form of urticaria with a pathogenesis that is poorly understood. It affects all skin types, can be difficult to diagnose, and is challenging to manage effectively. We conducted a retrospective review of patients with SU in our institution. Read More

View Article and Full-Text PDF

Successful treatment of solar urticaria with UVA1 hardening in three patients.

Photodermatol Photoimmunol Photomed 2019 May 8;35(3):193-195. Epub 2019 Jan 8.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

Solar urticaria (SU) is an uncommon photodermatosis that presents with sensitivity to ultraviolet (UV) or visible light which triggers urticarial lesions. Treatment of SU is a challenge and usually involves antihistamines and photoprotection as a first-line treatment. Phototherapy regimens are recommended if these first-line treatments fail to control the disease. Read More

View Article and Full-Text PDF

Unexpected photosensitivity - a patient with dermatomyositis and concomitant solar urticaria.

J Eur Acad Dermatol Venereol 2019 Apr 9;33(4):e149-e150. Epub 2019 Jan 9.

Department of Dermatology and Allergy Biederstein, Technical University Munich, Munich, Germany.

View Article and Full-Text PDF

Solar Angioedema: A report of a patient and a review of literature.

Photodermatol Photoimmunol Photomed 2019 05 6;35(3):187-189. Epub 2019 Jan 6.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

View Article and Full-Text PDF

Afamelanotide in the Treatment of Dermatologic Disease

Skin Therapy Lett 2018 11;23(6):6-10

Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA

Afamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments. Its efficacy has been demonstrated in several dermatologic conditions, including erythropoietic protoporphyria (EPP), solar urticaria, polymorphic light eruption (PMLE), vitiligo, acne, and Hailey-Hailey disease. Its relatively low risk side effect profile makes it an attractive treatment option and also paves the way for innovative use in other disorders. Read More

View Article and Full-Text PDF
November 2018

Evaluating patient responses to omalizumab in solar urticaria.

Photodermatol Photoimmunol Photomed 2019 Jan 25;35(1):57-65. Epub 2018 Nov 25.

Centre for Dermatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

View Article and Full-Text PDF
January 2019